

Date : 13/08/2007

IDENTIFICATION

Family name:	Willan	CFI PIN : 51087
Given name and initials:	Andrew R	
Position:	Senior Scientist	
Institution:	The Hospital for Sick Children	
Department:	Child Health Evaluative Sciences	

MAILING ADDRESS (including institution, street and number, municipality, province, and postal code):

Child Health Evaluative Sciences Research Institute Hospital for Sick Children 555 University Avenue			
Toronto			
Ontario			
M5G 1X8			
CANADA			
Office Telephone:	(416) 8132166	Extension:	Fax:
E-mail address:	andy@andywillan.com		
I wish to receive correspondence in: <input checked="" type="radio"/> English <input type="radio"/> French			

ACADEMIC BACKGROUND

Degree type	Year received or expected	Discipline/Field/Speciality	Institution and Country
Doctorate (PhD)	1979	Biostatistics	University of Western Ontario CANADA
Master's	1976	Statistics	Queen's University at Kingston CANADA
Bachelor's	1972	Education	Queen's University at Kingston CANADA
Bachelor's	1970	Economics and Mathematics	York University CANADA

Name: Willan, Andrew

AREA(S) OF EXPERTISE

List up to ten keywords that best correspond to your areas of expertise in research, creation, instrumentation and techniques.

Biostatistics, Clinical Trials, Health Economic Analysis, Crossover Designs, Meta-analysis

Specify up to three discipline/subdiscipline code(s) for your research.

Discipline: STATISTICS AND PROBABILITY

Subdiscipline: Biostatistics

Discipline: EPIDEMIOLOGY

Subdiscipline: Clinical Trials/Clinical Trial Design

Discipline: EPIDEMIOLOGY

Subdiscipline: Health Economics

PROFESSIONAL EXPERIENCE

Position / Organization	Department / Division	Period	
		Start date	End date
Professor Emeritus McMaster University	Clinical Epidemiology and Biostatistics	2002	
Full Professor University of Toronto	Public Health Sciences	2002	
Senior Scientist The Hospital for Sick Children	Child Health Evaluative Sciences	2002	
Full Professor McMaster University	Clinical Epidemiology and Biostatistics	1993	2002
Associate Professor McMaster University	Clinical Epidemiology and Biostatistics	1990	1993
Associate Professor University of Toronto	Preventive Medicine & Biostatistics	1989	1991
Department Chair/Head Sunnybrook and Women's College Health Sciences Centre	Cancer Program/Clinical Trials & Epidemiology	1989	1990
Associate Professor University of Guelph	Population Medicine	1987	1988

Name: Willan, Andrew

RESEARCH CONTRIBUTION IN THE LAST FIVE YEARS

SAMPLE PUBLICATIONS (2004-2008)

1. **Willan AR**, Chen E, Cook RJ, Lin DY. Incremental net benefit in randomized clinical trials with qualify-adjusted survival. *Statistics in Medicine* 2003; **22**: 353-362.
2. Sears MR, Greene JM, **Willan AR**, Wiecek, EM, Taylor DR, Flannery EM, Cowan JO, Herbison GP, Silva PA, Poulton R. Persistence, remission and relapse of childhood asthma followed to adulthood: a longitudinal population-based cohort study. *NEJM* 2003; **349(15)**: 1414-1422.
3. **Willan AR**. Incremental net benefit in the analysis of economic data from clinical trials with application to the CADET-Hp Trial. *European Journal of Gastroenterology and Hepatology* 2004; **16**: 543-549.
4. **Willan AR**, Briggs AH, Hoch JS. Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. *Health Economics* 2004; **13**: 461-475.
5. Briggs AH, Buxton M, Drummond M, Goeree R, Sculpher MJ, **Willan AR**. Unfinished Symphony: A Tribute to the Life and Career of Bernie O'Brien (1959-2004). *Medical Decision Making* 2004; **24**: 538-544.
6. **Willan AR**, Lin DY, Manca A. Regression methods for cost-effectiveness analysis with censored data. *Statistics in Medicine* 2005; **24**: 131-145.
7. **Willan AR**, Pinto EM, O'Brien BJ, Kaul P, Goeree R, Lynd L, Armstrong PW. Country specific cost comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: the Canadian ASSENT-3 economic analysis. *Health Economics* 2005; **14**: 327-328.
8. **Willan AR**, Pinto EM. The expected value of information and optimal clinical trial design. *Statistics in Medicine* 2005; **24**: 1791-1806.
9. Pinto EM, **Willan AR**, O'Brien BJ. Cost-effectiveness analysis for multinational clinical trials. *Statistics in Medicine* 2005; **24**: 1965-1982.
10. O'Hagan A, McCabe C, Akehurst R, Brennan A, Briggs A, Claxton K, Fenwick E, Fryback D, Sculpher M, Spiegelhalter M and **Willan AR**. Incorporation of uncertainty in health economic modelling studies. *Pharmacoeconomics* 2005; **23(6)**: 529-36.
11. Reed SD, Anstrom KJ, Bakhai A, Briggs AH, Califf RM, Cohen DJ, Drummond MF, Glick HA, Gnanasakthy A, Hlatky MA, O'Brien BJ, Torti FM, Tsiatis AA, **Willan AR**, Mark DB, Schulman KA. Conducting economic evaluations alongside multinational clinical trials: Toward a research consensus. *American Heart Journal* 2005; **149(3)**: 434-443.
12. **Willan AR**, Goeree, R, Pinto EM, McBurney C, Blackhouse G. Economic Evaluation of Rivastigmine in Patients with Parkinson's Disease Dementia. *Pharmacoeconomics* 2006; **24**: 93-106.

13. Palencia R, Gafni A, Hannah ME, Ross S, **Willan AR** et al. The costs of planned caesarean versus planned vaginal birth in the Term Breech Trial. *CMAJ* 2006; **174**: 1109-1113.
14. **Willan AR**, Briggs AH. *The Statistical Analysis of Cost-effectiveness Data*. Chichester UK: Wiley 2006.
15. Sofronas M, Ichord RN, Fullerton HJ, Lynch JK, Massicotte MP, **Willan AR**, deVeber G. Pediatric stroke initiatives and preliminary studies: what is known and what is needed? *Pediatric Neurology* 2006; **34**: 439-445.
16. **Willan AR**. Statistical analysis of cost-effectiveness data from randomized clinical trials. *Expert Rev. Pharmacoeconomics Outcomes Res.* 2006; **6**:337-346.
17. Manca A, **Willan AR**. Lost in translation”: accounting for between country differences in the analysis of multinational cost effectiveness data. *Pharmacoeconomics* 2006; **24**: 1101-1119.
18. Eckermann S, **Willan AR**. Expected value of information and decision making in HTA. *Health Economics* 2007; **16**: 195-209.
19. Pullenayegum EM, **Willan AR**. Semi-parametric regression models for cost-effectiveness analysis: improving the efficiency of estimation from censored data. *Statistics in Medicine* 2007; **26**: 3274-3299.
20. **Willan AR**. Clinical decision making and the expected value of information. *Clinical Trials* 2007; **4**: 279-285.
21. Hossain A, **Willan AR**. Approximate MLEs of the parameters of location-scale models under type II censoring. *Statistics* 2007; **41**(5): 385-394.
22. Boutis K, **Willan AR**, Babyn P, Narayanan UG, Alman B, Schuh S. A randomized, controlled trial of a removable brace versus casting in children with low-risk ankle fractures. *Pediatrics* 2007; **119**(6): e1256-e1263.
23. Eckermann S, **Willan AR**. Time and EVSI wait for no patient. *Value in Health* 2008; **11**: 522-526.
24. **Willan AR**, Kowgier ME. Cost-effectiveness Analysis of a Multinational RCT with a Binary Measure of Effectiveness and an Interacting Covariate. *Health Economics* 2008; **17**: 777-791.
25. Eckermann S, **Willan AR**. The option value of delay in health technology assessment. *Medical Decision Making*, 2008 **28**: 300-305.
26. Eckermann S, Briggs A, **Willan AR**. Health technology assessment in the cost-disutility plane. *Medical Decision Making* 2008; **28**: 172-181.
27. Eckermann S, **Willan AR**. Globally optimal trial design for local decision making. *Health Economics*, published online: Apr 24 2008. DOI: 10.1002/hec.1353.
28. **Willan AR**, Kowgier ME. Determining optimal sample sizes for multi-stage randomized clinical trials using value of information methods. *Clinical Trials* 2008; **5**: 289-300.
29. **Willan AR**. Optimal sample size determinations from an industry perspective based on the expected value of information. *Clinical Trials* 2008; **5**: 587-594.
30. Murphy KE, Hannah ME, **Willan AR** et al. Multiple courses of antenatal corticosteroids for preterm birth study (MACS): a randomised controlled trial. *Lancet* 2008; **372**:2143-2151.